登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC
ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由复旦大学附属中山医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07833241,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Patients with high-risk resectable or borderline resectable pancreatic adenocarcinoma confirmed by histopathology or cytology. (The definition of borderline resectable pancreatic pancreatic cancer refers to the NCCN Guidelines 2026 (Version 1). High-risk resectable disease is defined as meeting all three of the following criteria:
入选标准第 3 条
Male and female patients of reproductive potential agree to use effective contraceptive methods throughout the study period and for 6 months after the last study drug administration, such as dual-barrier contraception, condoms, oral or injectable contraceptives, intrauterine devices, etc. All female patients will be considered of reproductive potential unless they have natural menopause, induced menopause, or sterilization procedures (e.g., hysterectomy, bilateral adnexectomy, ovarian radiation, etc.).
入选标准第 11 条
Pregnant females (positive pregnancy test prior to study drug administration) or lactating females.
排除标准第 14 条
Patients with active autoimmune or inflammatory diseases requiring systemic therapy within the previous 2 years (i.e., disease-modifying agents, glucocorticoids or immunosuppressive agents); or diseases treated with long-term systemic hormones or any other immunosuppressive drugs (excluding inhaled corticosteroids).
排除标准第 17 条
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
入选标准第 7 条
Have at least one measurable lesion per RECIST 1.1.
入选标准第 4 条
History of other malignancies within the past 5 years, except for radically resected basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
排除标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07833241,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Have fully understood this study and voluntarily signed the informed consent form. Aged between 18 and 75 years inclusive, of any gender. Patients with high-risk resectable or borderline resectable pancreatic adenocarcinoma confirmed by histopathology or cytology. (The definition of borderline resectable pancreatic pancreatic cancer refers to the NCCN Guidelines 2026 (Version 1). High-risk resectable disease is defined as meeting all three of the following criteria: Have at least one measurable lesion per RECIST 1.1. No pathogenic BRCA1/2 or PALB2 mutations, or unknown BRCA1/2 and PALB2 mutation status. No prior systemic anti-tumor therapy or locoregional radiotherapy. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Expected survival ≥ 24 weeks. Absence of contraindications to surgery. Laboratory hematology parameters (without blood transfusion within the preceding 14 days): Male and female patients of reproductive potential agree to use effective contraceptive methods throughout the study period and for 6 months after the last study drug administration, such as dual-barrier contraception, condoms, oral or injectable contraceptives, intrauterine devices, etc. All female patients will be considered of reproductive potential unless they have natural menopause, induced menopause, or sterilization procedures (e.g., hysterectomy, bilateral adnexectomy, ovarian radiation, etc.).排除标准:Exclusion Criteria:
Patients with distant metastasis. Patients who have received blood transfusion, blood products or hematopoietic growth factors (such as albumin and granulocyte colony-stimulating factor [G-CSF]) within 14 days prior to enrollment. Patients who have undergone any surgery or invasive treatment/procedure within 4 weeks prior to enrollment (except venous catheterization, puncture and drainage, etc.). Known hypersensitivity to any study drug. Uncontrolled hypertension defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg. Patients with any disease or condition affecting drug absorption, or patients unable to receive oral surufatinib. Patients with active gastrointestinal diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresected tumors, or other conditions judged by the investigator to carry risks of gastrointestinal bleeding or perforation. Uncontrolled malignant ascites (defined as ascites that cannot be controlled by diuretics or paracentesis as assessed by the investigator). Patients with evidence or history of obvious bleeding tendency within 3 months prior to enrollment (bleeding >30 mL within 3 months, hematemesis, melena, hematochezia), hemoptysis (fresh blood >5 mL within 4 weeks), or thromboembolic events within 10 months (including stroke and/or transient ischemic attack [TIA]). Clinically significant electrolyte abnormalities as judged by the investigator. Significant clinically relevant cardiovascular diseases, including but not limited to: acute myocardial infarction, severe/unstable angina or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) class >2 congestive heart failure; ventricular arrhythmias requiring pharmacological treatment; left ventricular ejection fraction (LVEF) <50%. History of other malignancies within the past 5 years, except for radically resected basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix. Active or uncontrolled severe infections: Pregnant females (positive pregnancy test prior to study drug administration) or lactating females. The investigator judges that the subject has any clinical or laboratory abnormality or other conditions rendering the subject unsuitable for participation in this clinical study. Urinalysis showing urine protein ≥2+, with 24-hour urinary protein quantification >1.0 g. Patients with active autoimmune or inflammatory diseases requiring systemic therapy within the previous 2 years (i.e., disease-modifying agents, glucocorticoids or immunosuppressive agents); or diseases treated with long-term systemic hormones or any other immunosuppressive drugs (excluding inhaled corticosteroids). Patients with hypothyroidism/adrenal or pituitary insufficiency who only require stable hormone replacement therapy, as well as patients with type 1 diabetes mellitus with stable disease managed solely by insulin replacement, are eligible for enrollment. History of (non-infectious) pneumonia requiring steroid treatment; past or current history of interstitial lung disease, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, pulmonary fibrosis or other lung diseases resulting in severely impaired pulmonary function; or active pulmonary infection at present. Receipt of any live or attenuated live vaccine within 4 weeks before the first study drug administration, or planned administration of such vaccines during the study period.
引自 ClinicalTrials.gov, NCT07833241, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07833241,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。